RU2558835C2 - Способы применения sns-595 для лечения субъектов с онкологическими заболеваниями, имеющих сниженную активность brca2 - Google Patents

Способы применения sns-595 для лечения субъектов с онкологическими заболеваниями, имеющих сниженную активность brca2 Download PDF

Info

Publication number
RU2558835C2
RU2558835C2 RU2011139323/15A RU2011139323A RU2558835C2 RU 2558835 C2 RU2558835 C2 RU 2558835C2 RU 2011139323/15 A RU2011139323/15 A RU 2011139323/15A RU 2011139323 A RU2011139323 A RU 2011139323A RU 2558835 C2 RU2558835 C2 RU 2558835C2
Authority
RU
Russia
Prior art keywords
sns
naphthyridine
thiazolyl
oxo
pyrrolidinyl
Prior art date
Application number
RU2011139323/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2011139323A (ru
Inventor
Рейчал Э. ХОТИН
Джудит А. ФОКС
Original Assignee
Санесис Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санесис Фармасьютикалз, Инк. filed Critical Санесис Фармасьютикалз, Инк.
Publication of RU2011139323A publication Critical patent/RU2011139323A/ru
Application granted granted Critical
Publication of RU2558835C2 publication Critical patent/RU2558835C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2011139323/15A 2009-02-27 2010-03-01 Способы применения sns-595 для лечения субъектов с онкологическими заболеваниями, имеющих сниженную активность brca2 RU2558835C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15644909P 2009-02-27 2009-02-27
US61/156,449 2009-02-27
US17001309P 2009-04-16 2009-04-16
US61/170,013 2009-04-16
PCT/US2010/025737 WO2010099526A1 (en) 2009-02-27 2010-03-01 Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity

Publications (2)

Publication Number Publication Date
RU2011139323A RU2011139323A (ru) 2013-04-10
RU2558835C2 true RU2558835C2 (ru) 2015-08-10

Family

ID=42224275

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011139323/15A RU2558835C2 (ru) 2009-02-27 2010-03-01 Способы применения sns-595 для лечения субъектов с онкологическими заболеваниями, имеющих сниженную активность brca2

Country Status (14)

Country Link
US (3) US20120148564A1 (enExample)
EP (2) EP2400959A1 (enExample)
JP (2) JP5936862B2 (enExample)
KR (2) KR20110132400A (enExample)
CN (2) CN104688732A (enExample)
AU (2) AU2010217796B2 (enExample)
CA (1) CA2753261A1 (enExample)
IL (1) IL214784A0 (enExample)
MX (1) MX348412B (enExample)
NZ (1) NZ594829A (enExample)
RU (1) RU2558835C2 (enExample)
SG (2) SG10201400258SA (enExample)
WO (1) WO2010099526A1 (enExample)
ZA (1) ZA201106199B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005222622B2 (en) 2004-03-15 2011-04-07 Dainippon Sumitomo Pharma Co., Ltd. SNS-595 and methods of using the same
AU2008317400B2 (en) 2007-10-22 2014-10-02 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino) -1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3- carboxylic acid in combination therapy
EP3284745A1 (en) 2008-12-31 2018-02-21 Sunesis Pharmaceuticals, Inc. Composition of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
CN104688732A (zh) * 2009-02-27 2015-06-10 逊尼希思制药公司 利用sns-595治疗具有降低的brca2活性的癌症对象的方法
UA110465C2 (en) 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition
US8470817B2 (en) 2009-10-26 2013-06-25 Sunesis Pharmaceuticals, Inc. Compounds and methods for treatment of cancer
WO2023110045A1 (en) 2021-12-15 2023-06-22 Y-Mabs Therapeutics, Inc. Scfv and antibodies with reduced multimerisation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007028171A1 (en) * 2005-09-02 2007-03-08 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
RU2006121459A (ru) * 2003-12-01 2008-01-10 КуДОС Фармасьютикалс Лимитед (GB) Ингибиторы репарации повреждения днк для лечения рака
WO2008121132A2 (en) * 2007-03-30 2008-10-09 Source Precision Medicine, Inc. D/B/A Source Mdx Gene expression profiling for identification, monitoring, and treatment of prostate cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6024A (en) * 1849-01-09 Cast-iron gar-wheel
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
ATE209645T1 (de) 1994-06-14 2001-12-15 Dainippon Pharmaceutical Co Neue verbindung, verfahren zu ihrer herstellung und antitumormittel
JPH10173986A (ja) 1996-12-16 1998-06-26 Sony Corp 移動体撮影装置
AU2005222622B2 (en) 2004-03-15 2011-04-07 Dainippon Sumitomo Pharma Co., Ltd. SNS-595 and methods of using the same
MX2008015775A (es) 2006-06-12 2009-04-17 Sunesis Pharmaceuticals Inc Compuestos y composiciones para tratamiento de cancer.
US7790274B2 (en) 2006-08-02 2010-09-07 High Impact Technology, Llc Layered panel structure including self-bonded thermoformable and non-thermoformable layer materials
CN104688732A (zh) * 2009-02-27 2015-06-10 逊尼希思制药公司 利用sns-595治疗具有降低的brca2活性的癌症对象的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006121459A (ru) * 2003-12-01 2008-01-10 КуДОС Фармасьютикалс Лимитед (GB) Ингибиторы репарации повреждения днк для лечения рака
WO2007028171A1 (en) * 2005-09-02 2007-03-08 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
WO2008121132A2 (en) * 2007-03-30 2008-10-09 Source Precision Medicine, Inc. D/B/A Source Mdx Gene expression profiling for identification, monitoring, and treatment of prostate cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MILLS DA et al. "SNS-595, a naphthyridine cell cycle inhibitor and stimulator of apoptosis for the treatment of cancer". Curr Opin Investig Drugs, 2008 Jun;9(6):647-57. EVANS JW et al. "Homologous recombination is the principal pathway for thq repair of DNA damage induced by tirapazamine in mammalian cells". Cancer Rev 2008 Jan1;68(1):257-65, реферат, найдено 10.02.2014, найдено из PubMed PMID:18172318 *

Also Published As

Publication number Publication date
AU2010217796B2 (en) 2015-04-30
ZA201106199B (en) 2012-10-31
JP2012523376A (ja) 2012-10-04
KR20170046193A (ko) 2017-04-28
AU2010217796A1 (en) 2011-09-15
NZ594829A (en) 2013-09-27
JP2015145396A (ja) 2015-08-13
SG173855A1 (en) 2011-09-29
RU2011139323A (ru) 2013-04-10
KR20110132400A (ko) 2011-12-07
US20170182015A1 (en) 2017-06-29
CN104688732A (zh) 2015-06-10
US20150202189A1 (en) 2015-07-23
CA2753261A1 (en) 2010-09-02
JP5936862B2 (ja) 2016-06-22
SG10201400258SA (en) 2014-05-29
CN102405045A (zh) 2012-04-04
MX2011008994A (es) 2011-09-15
IL214784A0 (en) 2011-11-30
MX348412B (es) 2017-06-12
WO2010099526A1 (en) 2010-09-02
AU2015207901A1 (en) 2015-08-20
US20120148564A1 (en) 2012-06-14
EP3287126A1 (en) 2018-02-28
EP2400959A1 (en) 2012-01-04

Similar Documents

Publication Publication Date Title
RU2558835C2 (ru) Способы применения sns-595 для лечения субъектов с онкологическими заболеваниями, имеющих сниженную активность brca2
US11260057B2 (en) Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer
AU2017417160A1 (en) Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptor alpha
EP2512469B1 (en) 3-(indolyl)-or 3-(azaindolyl)- 4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarzinoma
CN110934873B (zh) 靶向组织微环境中衰老细胞的抗衰老药物d/s及其应用
TW202233177A (zh) 治療黑色素瘤的藥物組合的用途
US20240343728A1 (en) Compounds that inhibit pi3k isoform alpha and methods for treating cancer
WO2023091746A1 (en) Combination therapy comprising an fgfr inhibitor and a kras inhibitor
CN117487915A (zh) H2afv在肝癌诊断、预后、预防或治疗中的应用
CN112439067B (zh) Sglt2抑制剂在制备改善抗肿瘤药物敏感性的产品中的应用
JP2015515476A (ja) Ｐｉ３ｋ阻害剤及びｍｅｋ阻害剤を使用する癌の治療方法
UA103917C2 (uk) Застосування sns-595 для лікування суб'єктів з онкологічними захворюваннями, які мають знижену активність brca2
WO2025199434A1 (en) Methods of treating breast cancer using a pyrazole compound
IL322689A (en) Compositions and methods of using eflornithine
HK40029376B (en) Drug therapy to inhibit chemotherapy-induced adverse effects and screening techniques and kits
CN118632696A (zh) 包含fgfr抑制剂和kras抑制剂的组合疗法
CN115887455A (zh) 钙离子通道阻滞剂阿折地平在制备治疗子宫内膜癌的药物中的应用
HK40031991B (zh) 治疗和预防移植物抗宿主病的方法
HK40029376A (en) Drug therapy to inhibit chemotherapy-induced adverse effects and screening techniques and kits

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20180302